Our first edition of 2022 focuses on Healthcare and Life Sciences. It is a sector that will once again have the spotlight on it this year as we continue to tackle COVID-19 and its subsequent variants. While the pandemic continues to challenge the sector, governments across the region forge ahead with their plans to expand and upgrade healthcare systems and develop robust world-class healthcare infrastructure.
For the region, healthcare is a vital pillar in diversifying its economies, both locally and as medical tourism hubs. To underpin this, healthcare authorities across the region continue to implement frameworks and regulations that provide structure and accountability.
In this edition, you have unique access to great insights and expert commentary on a number of pertinent healthcare regulatory developments. You will find a topical mix of articles; for example, our lawyers discuss vaccines and returning to work during the pandemic. They take you through several other areas, including stem cell research in Bahrain, clinical research laws in Egypt, and Saudi medical device and pharmaceutical laws.Take a read of the edition
Al Tamimi & Company offers access to a brilliant range of M&A specialist lawyers, all of them practicing in the Middle East and North Africa (MENA). This deep specialist expertise and broad regional footprint arms us with capabilities to lead transactional negotiation, to conduct timely and credible due diligence reviews, to execute any restructuring rapidly and to handle regulatory issues and close deals in MENA countries.
We have handled many of the most significant and high-value M&A deals in the MENA region. In regional cross-border transactions, we offer an unsurpassed combination of specialist legal skills attuned to MENA’s legal systems, and a network of lawyers practicing in nine countries in the region.
Our deal capabilities extend across all key work streams in the M&A legal process, including deal negotiation and transaction documents, due diligence and disclosure carve-outs, pre-closing restructuring, regulatory approvals and deal closings for both share and asset transactions.